Your Article Summary
See Latest ArticlesGolimumab (Simponi): Anti-TNF-alpha mAb approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
Formulary , 06/09/09
Tumor necrosis factor (TNF)-alpha is a mediator of articular inflammation in chronic inflammatory diseases. Golimumab is a human monoclonal antibody that binds to human TNF-alpha, thus inhibiting its activity. Golimumab was approved on April 2009, for use alone or in combination with methotrexate for the treatment of adult patients with active psoriatic arthritis, for use in combination with methotrexate for the treatment of adult patients with moderately to severely active rheumatoid arthritis, and for the treatment of adult patients with active ankylosing spondylitis.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09